18 studies found for:    TAK-700
Show Display Options
Rank Status Study
1 Completed Safety Study of TAK-700 in Subjects With Prostate Cancer.
Condition: Prostatic Neoplasms
Intervention: Drug: TAK-700
2 Completed Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: orteronel 200mg/300mg;   Drug: orteronel 200mg/400mg;   Drug: Placebo
3 Active, not recruiting NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis
Conditions: Prostatic Neoplasms;   Prostate Cancer
Intervention: Drug: TAK-700
4 Completed Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen
Condition: Prostate Cancer
Intervention: Drug: TAK-700
5 Recruiting S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: TAK-700;   Drug: Bicalutamide
6 Completed Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: TAK-700;   Drug: Docetaxel;   Drug: Prednisone
7 Recruiting Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.
Condition: Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors
Intervention: Drug: Orteronel 300mg BID
8 Completed Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: Orteronel+Prednisone
9 Withdrawn TAK-700 in Castration Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Orteronel;   Drug: Bicalutamide
10 Recruiting CO11109: A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer
Condition: Post Menopausal, Hormone Receptor Positive Breast Cancer
Intervention: Drug: TAK700
11 Not yet recruiting Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents
Condition: Prostate Cancer
Interventions: Drug: Orteronel;   Drug: Placebo
12 Recruiting Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Condition: Metastatic Breast Cancer
Intervention: Drug: Orteronel
13 Recruiting Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: orteronel;   Other: laboratory biomarker analysis
14 Recruiting Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin acetate;   Drug: leuprolide acetate;   Drug: orteronel;   Drug: triptorelin
15 Recruiting Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy
Condition: Prostate Cancer
Interventions: Drug: Orteronel;   Drug: Placebo
16 Withdrawn Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC)
Conditions: Prostate Cancer;   Castration-resistant Prostate Cancer
Interventions: Drug: Itraconazole;   Drug: Orteronel
17 Completed Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone;   Drug: Placebo + prednisone
18 Active, not recruiting Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone;   Drug: Placebo + prednisone

Indicates status has not been verified in more than two years